

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 1 069 902 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
**11.02.2004 Bulletin 2004/07**

(51) Int Cl.7: **A61K 31/685, A61P 41/00**

(21) Application number: **98955792.1**

(86) International application number:  
**PCT/GB1998/003540**

(22) Date of filing: **26.11.1998**

(87) International publication number:  
**WO 1999/051244 (14.10.1999 Gazette 1999/41)**

### (54) USE OF PHOSPHOLIPIDS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION OF ADHESIONS

VERWENDUNG VON PHOSPHOLIPIDEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR  
VORBEUGUNG VON ADHÄSIONEN

UTILISATION DE PHOSPHOLIPIDES POUR LA FABRICATION D'UN MEDICAMENT SERVANT A  
PREVENIR LES ADHESIONS

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT  
SE**

(74) Representative: **Woodcraft, David Charles  
Brookes Batchellor  
102-108 Clerkenwell Road  
London EC1M 5SA (GB)**

(30) Priority: **03.04.1998 GB 9807298**

(56) References cited:  
**EP-A- 0 528 034 WO-A-91/12026  
WO-A-98/53800**

(43) Date of publication of application:  
**24.01.2001 Bulletin 2001/04**

(73) Proprietor: **BRITANNIA PHARMACEUTICALS  
LIMITED  
Redhill, Surrey RH1 5TS (GB)**

- **M.SNOJ ET AL.: "Effect of phosphatidylcholine on postoperative adhesions after small bowel anastomosis in the rat" BR J SURG, vol. 79, no. 5, 1992, pages 427-429, XP002098866**
- **AAMER AR'RAJAB ET AL.: "Phosphatidylcholine prevents postoperative adhesions: An experimental study in the rat" J SURG RES, vol. 50, no. 3, 1991, pages 212-215, XP002098867**

(72) Inventors:

- **HILLS, Brian, Andrew  
Cleveland, QLD 4163 (AU)**
- **WOODCOCK, Derek, Alan  
Hertfordshire HP4 3HX (GB)**

EP 1 069 902 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description**

[0001] This invention relates to medicaments for reducing the probability of surgical adhesions.

[0002] Following surgery, membranes which have been severed may 'cross-heal'. For example the abdominal wall can heal with the peritoneum and adhere to it. This is known as an adhesion. A very serious complication of adhesions inside the peritoneum is intestinal obstruction. Unless corrected surgically this can rapidly be fatal. It has been estimated that in the US in 1988 the cost of correcting lower abdominal pelvic adhesions was of the order of US\$1180 million (AH de Cherney and GS diZeregram Surgical Clinics of North America 77(3), 671). Attempts have been made to reduce adhesions by providing physical barriers such as sheets of hyaluronic acid and carboxymethylcellulose. While providing an initial barrier the sheets degrade.

[0003] It has now been unexpectedly found that natural occurring surface active phospholipids and enantiomers thereof can substantially reduce the likelihood of adhesions forming when administered as a dry powder.

[0004] International application WO 91/12026 discloses the use of a phospholipid, preferably phosphatidyl choline, for reduction or prevention of unwanted surgical adhesion. The phospholipid is administered in the form of suspension or solution in a surgically acceptable carrier.

[0005] Snoj et al. (Br. J. Surg., 1992, Vol. 79, 427-429) and Aamer et al. (J. Surg. Research, 1991, Vol. 50, 212-215) disclose that intraperitoneal injection of phosphatidyl choline prevents postoperative peritoneal adhesions in rat.

[0006] The present invention provides the use of a surface active phospholipid composition (SAPL) composition in the manufacture of a medicament for use in reducing the probability of adhesions following surgery, wherein the medicament is in the form of a dry powder for administration as a dry powder, and is a SAPL composition which comprises a phosphatidyl choline and a spreading agent.

[0007] Embodiments of the invention will be described by way of non-limiting example by reference to the Figure which shows the length of adhesion formed under various conditions.

[0008] A physical or chemical binding of the surfactant to the membrane is highly desirable. Examples of suitable phospholipids include diacyl phosphatidyl cholines (DAPC's) such as dipalmitoyl phosphatidyl choline (DPPC), dioleyl phosphatidyl choline (DOPC) and distearyl phosphatidyl choline (DSPC). The SAPL composition also includes a spreading agent to assist the DPPC or analogous compound rapidly to form a thin film over the surface of the membrane. A number of agents are capable of acting in this way including other phospholipids, such as phosphatidylglycerols (PG); phosphatidylethanolamines (PE); phosphatidylserines (PS) and phosphatidylinositol (PI). Another useful spreading agent is cholestryl palmitate (CP). We prefer to use dipalmitoyl phosphatidyl choline (DPPC) and unsaturated phosphatidyl glycerol (PG) either alone or in combination. A mixture comprising DPPC 70 wt% and PG 30 wt% can be used. This material is commercially available as ALEC™ from Britannia Pharmaceutical Limited. ALEC is known for use in treating respiratory distress syndrome see for example British Medical Journal 294 (1984) 991-996.

[0009] A widely accepted theory on the mechanism of action of ALEC in the lungs of neonates is that it functions principally by lowering surface tension. Since there is no air-water interface in the normal peritoneal cavity one would not expect ALEC and other SAPL's to be effective in preventing the formation of or reduction the probability of forming adhesions. It has however been experimentally found that SAPL's administered in the form of dry powder do, in fact reduce the frequency of adhesion formation as will become apparent from the experimental data set forth below.

[0010] 40 rabbits were taken. A surgical opening was made in the peritoneum. Opposing peritoneal surfaces were subjected to a sterilised 50 mm abrasion. In 10 cases the opening was simply closed. In a further 10 cases the abrasion was perfused with dialysate prior to closure. In a still further 10 cases the abrasion was perfused with a suspension of ALEC in dialysate and the opening closed. In a final 10 cases powdered ALEC was blown into the abrasion prior to closure. Following healing the peritoneum was reopened and the presence of adhesions noted. Where adhesions were noted their length was measured. The results are shown in Table 1.

Table 1

	Control	Dialysate	ALEC & Dialysate	ALEC
Number of adhesion free cases	1	5	4	5
Total length of adhesion (mm)	320	197	151	91
Reduction in adhesion length relative to control	-	38%	53%	72%

Table 1 (continued)

	Control	Dialysate	ALEC & Dialysate	ALEC
5	Mean Adhesive Length (mm)	32	19.7	15.1
	Standard Deviation	5	10.5	9
				5

[0011] One can say therefore with a high degree of confidence (even with a very limited number of samples) that ALEC powder markedly reduces both the likelihood of adhesion formation and the length of the adhesions which do form. There is also evidence that a suspension of ALEC is more effective than either no treatment or treatment with dialysate.

[0012] The SAPL is used in the form of a dry powder aerial dispersion.

[0013] Phosphatidyl glycerol (PG) is believed to be capable of binding to the surface of the animal tissue and is, therefore, a preferred component of the SAPL. Dipalmitoyl phosphatidyl choline (DPPC) may function also in this way and is also a preferred compound of the SAPL. PG has a further important function in medicaments employed in the present invention which is its ability to cause the DPPC to form a dry powder. The particle size of such powders is not critical and the controlling factor is that the size is preferably such that medicament can be readily instilled into the surgical site. Generally, the particle size is within the range of 0.5 to 100 $\mu$ m. Particles which are more readily conveyed in a gas stream have a particle size of from 0.5 to 20 $\mu$ m, preferably 0.5 to 10 $\mu$ m and more preferably 0.5 to 2 $\mu$ m. Finely-divided dry powders of this kind are believed to be absorbed very rapidly onto the surfaces of mesothelial membranes, i.e. bound to the epithelium. Preferably, the SAPL compositions employed in the present invention are blends of dipalmitoyl phosphatidyl choline (DPPC) and PG, although as indicated above, other phospholipids may be employed.

[0014] The medicament should generally be essentially free from animal protein in order to avoid the danger of patient sensitivity to animal proteins. Also, animal proteins may become adhesive and, for this reason, should preferably be excluded from the compositions.

[0015] DPPC is commercially available from Sigma Chemical Co. Ltd. or can be prepared synthetically by the use of acyl chlorides using the method of Baer & Bachera - Can. J. Of Biochem. Physiol 1959; 37, page 953 and is available commercially from Sigma (London) Ltd. The PG may be prepared from egg phosphatidyl choline by the methods of Comfurions et al and Dawson, Biochem. Biophys Acta 1977; 488; pages 36-42 and Biochem J. 1947; 192; pages 205-210.

[0016] The medicaments employed in the present invention are generally finely-divided dry powders having a particle size distribution which is small enough to be introduced into the surgical site in a gas stream from a dispersion device. The material available commercially as 'Alec' has a particle size distribution such that a major proportion is between 0.5 and 2 $\mu$ m with a median particle diameter of about 1.2  $\mu$ m. However, as mentioned above, larger particle size powders can be satisfactorily used in accordance with the invention. The medicament of the present invention may be introduced into the surgical site through a cannula, e.g. connected to a syringe.

[0017] However, we prefer to employ a dispersion device which utilises a propellant. These may employ a propellant such as a halocarbon to form a gas stream and may include a tapered discharge nozzle, baffle or venturi to accelerate particles through a discharge nozzle. Suitable halocarbons include hydrofluorocarbons, hydrofluorochlorocarbons and fluorochlorocarbons having a low boiling point, such as those marketed by DuPont under the trade marks "Freon" and "SUVA". Pharmaceutically acceptable hydrofluoroalkanes are available as HFA-134a and 227.

[0018] One suitable design of dispensing device for administering the powdered material to a surgical site is shown in Figures 2 and 3 in which:-

Figure 2 is a side elevation of the dispenser; and

Figure 3 is a similar view, but shows its interior.

[0019] Referring to Figures 2 and 3, a casing (10) is formed from two plastic mouldings (12 & 13) which snap together to form a container for a pressurised canister (14) and a vial (15). Canister (14) contains a low boiling liquid, preferably a hydrofluorocarbon such as HFA-134a or HFC-227, under sufficient pressure to maintain the propellant liquid at normal room temperature. Vial (15) contains the powdered medicament, such as "Alec". Canister (14) has a release valve (16) which is received in a recess (17) so that finger pressure on the inverted end (18) of the canister will cause propellant to be released into a tube (19). Tube (19) is typically a hard plastics, e.g. pvc or polypropylene, tube of about

2-3 mm outside diameter and about 0.5 to 2 mm inside diameter. Tube (19) connects valve (16) with a fitting (20) and thence to a tube or needle (21) which extends into the vial (15). Vial (15) may be closed with a rubber seal which is penetrated by the tube or needle (21) and self-seals around the tube or needle. A second needle or tube (22) extends part way into the vial through the rubber seal in the neck of the vial and connects with a fitting (23). Fitting (23) discharges into a catheter (4) from which the powder can be directed to the desired area of the surgical site. The advantage of the dispenser shown in Figures 2 and 3 is that it can be operated 'one-handed' while the doctor or nurse ensures that the catheter is correctly positioned to distribute powder into the surgical site. A catheter may not be necessary. The powder may simply be sprayed onto the area of the surgical wound.

[0020] In general, the DPPC and PG may be present in a weight ratio of from 9:1 to 1:9. Compositions employed in current formulations have been in the weight ratio of from about 6:4 to 8:2.

[0021] It is desirable that the SAPL (or its active component) should not break down rapidly in the environment of the surgical wound. One of the factors which will reduce the life of a release lining or coating will be the presence of enzymes capable of digesting DPPC and/or PG. Such enzymes only attack the laevo rotatory (L) form, which constitutes the naturally occurring form. Therefore, the anti-adhesion medicament should preferably contain the dextro rotatory (D form) or at least comprise a racemic mixture which is obtained by synthetic preparation routes. This also applies to the other SAPL/s mentioned above.

[0022] The SAPL may comprise phosphatidyl glycerol (PG) either alone or in admixture with other components. PG has a useful additional function of forming very finely divided dispersions.

[0023] The SAPL may comprise dipalmitoyl phosphatidyl choline (DPPC) either alone or in admixture with other components such as PG.

[0024] In preferred embodiments the medicament is essentially free of animal protein to avoid patient sensitivity and also to aid the formation of finely divided particle.

[0025] When PG and DPPC are co-precipitated from a common solvent a fine powder is formed. At a weight ratio DPPC: PG of about 7:3 the mixture spreads rapidly at body temperature.

[0026] In general the weight ratio DPPC:PG lies in the range 9:1 to 1:9 preferably 6:4 to 8:2.

[0027] It may be advantageous to include other active substances into the medicament, such as anti-fungal or anti-bacterial agents.

### 30 Claims

1. Use of a surface active phospholipid composition (SAPL) composition in the manufacture of a medicament for use in reducing the probability of adhesions following surgery, wherein the medicament is in the form of a dry powder for administration as a dry powder, and is a SAPL composition which comprises a phosphatidyl choline and a spreading agent.
2. Use as claimed in claim 1 wherein the spreading agent is phosphatidyl glycerol (PG).
3. Use as claimed in claim 1 or 2 wherein the phosphatidyl choline is dipalmitoyl phosphatidyl choline (DPPC).
4. Use as claimed in claim 3 wherein the SAPL composition comprises a mixture of DPPC and PG at a weight ratio of 1:9 to 9:1.
5. Use as claimed in claim 3 wherein the weight ratio of DPPC:PG is 6:4 to 8:2.
6. Use as claimed in any one of the preceding claims wherein the SAPL composition is associated with a propellant for dispensing particles of the composition as a dry powder aerial dispersion.
7. Use according to claim 6 wherein the propellant is a hydrofluoroalkane.
8. Use according to any one of the preceding claims wherein the SAPL composition has a particle size of from 0.5 to 20 µm.

### 55 Patentansprüche

1. Verwendung einer oberflächenaktiven Phospholipidzusammensetzung (SAPL) in der Herstellung eines Arzneimittels zur Verwendung in der Reduzierung der Wahrscheinlichkeit von Adhäsionen nach chirurgischen Eingriffen,

wobei das Medikament in Form eines Trockenpulvers zur Anwendung als Trockenpulver verwendet wird und eine SAPL-Zusammensetzung ist, die ein Phosphatidylcholin und ein Verteilungsmittel umfasst.


2. Verwendung nach Anspruch 1, wobei das Verteilungsmittel Phosphatidylglycerol (PG) ist.
- 5 3. Verwendung nach Anspruch 1 oder 2, wobei das Phosphatidylcholin Dipalmitoyl-Phosphatidylcholin (DPPC) ist.
- 10 4. Verwendung nach Anspruch 3, wobei die SAPL-Zusammensetzung eine Mischung von DPPC und PG in einem Gewichtsverhältnis von 1:9 bis 9:1 umfasst.
- 15 5. Verwendung nach Anspruch 3, wobei das Mischungsverhältnis von DPPC:PG 6:4 bis 8:2 ist.
6. Verwendung nach einem der vorangehenden Ansprüche, wobei die SAPL-Zusammensetzung mit einem Treibmittel zur Ausgabe von Partikeln der Zusammensetzung als Trockenpulver-Luftdispersion assoziiert ist.
- 15 7. Verwendung nach Anspruch 6, wobei das Treibmittel ein Hydrofluoralkan ist.
8. Verwendung nach einem der vorangehenden Ansprüche, wobei die SAPL-Zusammensetzung eine Partikelgröße von 0,5 bis 20 µm aufweist.

#### **Revendications**

1. Utilisation d'une composition phospholipidique à surface active (SAPL) lors de la fabrication d'un médicament à utiliser pour réduire la probabilité d'adhésions après une opération chirurgicale, dans laquelle le médicament est sous la forme d'une poudre sèche à administrer sous la forme d'une poudre sèche, et est une composition de SAPL qui comprend une phosphatidylcholine et un agent de diffusion.
- 25 2. Utilisation selon la revendication 1, dans laquelle l'agent de diffusion est le phosphatidylglycérol (PG).
- 30 3. Utilisation selon la revendication 1 ou 2, dans laquelle la phosphatidylcholine est la dipalmitoyl phosphatidylcholine (DPPC).
- 35 4. Utilisation selon la revendication 3, dans laquelle la composition de SAPL comprend un mélange de DPPC et de PG en un rapport pondéral de 1:9 à 9:1.
5. Utilisation selon la revendication 3, dans laquelle le rapport pondéral de DPPC:PG est de 6:4 à 8:2.
6. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle la composition de SAPL est associée avec un propulseur pour distribuer les particules de la composition sous la forme d'une dispersion aérienne de poudre sèche.
- 40 7. Utilisation selon la revendication 6, dans laquelle le propulseur est un hydrofluoroalcane.
- 45 8. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle la composition de SAPL a une taille de particule de 0,5 à 20 µm.

50

55

**Fig. 1**




Fig. 2




Fig. 3